Loading...
•
Sep 30, 2024
Edwards Lifesciences Q3 2024 Earnings Report
Edwards Lifesciences reported third quarter results, showing sales growth and strategic focus on structural heart.
Key Takeaways
Edwards Lifesciences reported a 9% increase in sales from continuing operations, with constant currency sales growth of 10%. TAVR sales grew by 6%, while TMTT sales saw a significant increase of 73%. The company completed the sale of its Critical Care business and reiterated its full-year sales guidance.
Q3 sales from continuing operations grew 9%; constant currency sales grew 10%.
Q3 TAVR sales grew 6%; constant currency sales grew 7%.
TMTT sales grew 73%, driven by PASCAL and EVOQUE commercial launches.
Q3 EPS was $5.13; adjusted EPS was $0.67.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Edwards expects fourth quarter sales of $1.33 to $1.39 billion, and Q4 EPS of $0.53 to $0.57. Full year sales growth guidance of 8 to 10% remains unchanged.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...